未找到相关数据
First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer
被引：23
作者：
Baselga, J.
Bradbury, I.
Eidtmann, H.
Di Cosimo, S.
Aura, C.
De Azambuja, E.
Gomez, H.
Dinh, P.
Fauria, K.
Van Dooren, V.
Paoletti, P.
Goldhirsch, A.
Chang, T-W
Lang, I.
Untch, M.
Gelber, R. D.
Piccart-Gebhart, M.
机构：
[1] Vall dHebron Univ Hosp, NeoALTTO Study Team, Barcelona, Spain
[2] FSS Ltd, Kincraig, Scotland
[3] Univ Hosp Kiel, Kiel, Germany
[4] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain
[5] SOLTI Spanish Breast Canc Res Grp, Barcelona, Spain
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] Breast European Adjuvant Study Team, Brussels, Belgium
[8] Inst Nacl Enfermedades Neoplas, Lima, Peru
[9] Breast Int Grp, Brussels, Belgium
[10] GlaxoSmithKline, Collegeville, PA USA
[11] European Inst Oncol, Milan, Italy
[12] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[13] Natl Inst Oncol, Budapest, Hungary
[14] Charite, Acad Hosp, D-13353 Berlin, Germany
[15] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
关键词：
D O I：
10.1158/0008-5472.SABCS10-S3-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-3
引用
收藏
页数：2
相关论文